Core Insights - Daxor Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET [1] Company Overview - Daxor Corporation is addressing a significant issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays [3] - The company has developed a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor has 50 years of experience in the field and operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S., positioning it for market expansion [3] Investor Engagement - Investors interested in the presentation can register for the conference through a provided link [2] - CEO Michael Feldschuh will be available for one-on-one meetings with registered investors at the conference [2] - For further inquiries, investors can contact Bret Shapiro at CORE IR via phone or email [2][6]

Core Insights - Daxor Corporation has achieved FDA 510(k) clearance for its next-generation, rapid, compact, hand-held Blood Volume Analyzer (BVA), marking a significant milestone for the company [1] - The Nasdaq Closing Bell Ceremony held on August 8, 2025, celebrated this achievement and is now available for replay [2] Company Overview - Daxor Corporation is addressing a critical issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays for conditions like heart failure [3] - The company has over 50 years of experience in innovation and offers a patented, FDA-cleared Blood Volume Analysis diagnostic that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S. and is ISO certified, positioning itself for market expansion [3]

Core Insights - Daxor Corporation is expanding its blood volume measurement technology into East Tennessee and the Pacific Northwest, enhancing care for cardiovascular and critical care patients [1][2] - The company utilizes dual implementation models, including concierge laboratory services and on-site systems, to meet diverse clinical needs [2] - Daxor's proprietary technology, including the BVA-100® analyzer, is FDA-cleared and has been shown to reduce mortality, hospital readmissions, and length of stay for heart failure patients [3][5] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with over 70,000 tests performed in leading U.S. hospitals [3] - The company is involved in ongoing clinical trials for heart failure treatment, supported by the NIH, and is developing analyzers for combat casualty care with the U.S. Department of Defense [3] Recent Developments - A premier regional referral center in East Tennessee has integrated Daxor's ezBVA Lab service into its cardiology practice, providing diagnostic results within 24 hours [5] - A leading healthcare facility in the Pacific Northwest has implemented Daxor's on-site BVA analyzer system, facilitating immediate access to critical blood volume data for clinical decision-making [5]

Core Insights - Daxor Corporation has significantly expanded its blood volume analysis capabilities with the introduction of the ezBVA Lab service in three new hospitals, enhancing accessibility and operational efficiency in blood volume measurement [1][2] - The ezBVA Lab service is a CLIA-certified facility that provides precise blood volume analysis results within 24 hours, contributing to strong sales momentum as healthcare providers recognize its clinical and economic benefits [1][2] - Daxor's BVA-100® is the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition, with over 70,000 tests performed, leading to improved hospital performance metrics and reduced mortality and readmissions in heart failure and critical care [3] Recent Developments - The ezBVA Lab service has been adopted by leading healthcare providers, including a regional referral center in Philadelphia, a premier hospital in northern Kentucky, and a community hospital in Arkansas, all focusing on enhancing outpatient heart failure management [5] - Daxor's CEO highlighted the zero-capital investment model and full reimbursement coverage of the ezBVA Lab service as key factors driving its adoption across the nation [2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with a mission to advance healthcare through optimal fluid management via blood volume analysis [3] - The company is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3]

Core Insights - Daxor Corporation has submitted its next-generation blood volume analyzer, Daxor BVA, to the FDA, aiming to enhance healthcare through improved fluid management [1][3] - The Daxor BVA device offers direct quantification of intravascular blood, red blood cell, and plasma volume, representing a significant advancement over the previous Daxor BVA-100 system [2][3] - The new analyzer is designed to be three times faster in processing, simpler to operate, completely portable, and allows for point-of-care analysis [6] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, having developed the BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [4] - Over 65,000 tests have been conducted at major hospital centers in the U.S., contributing to improved performance metrics in various medical conditions, particularly in reducing mortality and readmissions in heart failure and critical care [4] - The company is engaged in ongoing trials for heart failure treatment with support from the NIH and is also developing analyzers for combat casualty care under a contract with the U.S. Department of Defense [4]

Core Insights - Daxor Corporation reported a strong financial performance for fiscal 2024, achieving a 116.5% increase in revenue compared to 2023, driven by robust demand for its diagnostic systems [4] - The company has successfully transitioned to cash-flow positive operations in Q1 of 2025, excluding non-cash expenses [4] - Daxor is focused on launching its next-generation blood volume analyzer, which is expected to enhance clinical workflows and open new market opportunities [2] Financial Highlights - The net asset value (NAV) per share increased to $7.25 for fiscal 2024 from $7.08 in 2023 [1] - Daxor signed 12 new accounts in 2024, resulting in a 60.1% growth in the number of diagnostic kits sold year-over-year [4] - The company secured a $2.5 million two-year contract from the Department of Defense, contributing to its commercial momentum [4] Operational Developments - Daxor's next-generation blood volume analyzer is set to be filed for FDA approval via the rapid 510(k) pathway, which will facilitate point-of-care blood volume measurements [2] - The first two months of 2025 saw record-breaking monthly kit revenue, indicating accelerating adoption of Daxor's products [4] - The company received over $350,000 in grants from NIH and Launch Tennessee to support ongoing research and development [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with its BVA-100 being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] - The company has performed over 65,000 tests at leading hospital centers across the U.S., significantly improving patient outcomes in various medical conditions [3] - Daxor is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care with the U.S. Department of Defense [3]